silver nitrate (Rx)

Brand and Other Names:
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

topical solution

  • 0.5%
  • 10%
  • 25%
  • 50%

applicator sticks

  • 75%

Antiseptic Wound Cauterization

Sticks: Apply to mucous membranes and other moist skin surfaces only on area to be treated

Topical solution: Apply a cotton applicator dipped in solution/ointment on the affected area 2-3 times per week for 2-3 weeks

Supralumbar Kertaconjunctivitis (Off-label)

Apply 0.5-1% solution to anesthetized upper tarsus, allow it to fall back into place over affected palpebral conjunctiva

Irrigate with sterile saline after 1 minute

May be repeated after 4-6 weeks

Dosage Forms & Strengths

topical solution

  • 0.5%
  • 10%
  • 25%
  • 50%

applicator sticks

  • 75%

Antiseptic Wound Cauterization

Sticks: Apply to mucous membranes and other moist skin surfaces only on area to be treated

Topical solution: Apply a cotton applicator dipped in solution/ointment on the affected area 2-3 times per week for 2-3 weeks

Next:

Interactions

Interaction Checker

and silver nitrate

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Frequency Not Defined

            Burning and skin irritation

            Staining of the skin

            Methemoglobinemia

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Broken skin, wounds, or cuts

            Cautions

            Avoid prolonged contact with skin or other surfaces since staining may occur

            May irritate skin & mucous membranes

            Do not irrigate eye after application of 1% solution

            Chemical burns may result from inapropriate use of product

            Skin contact time with applicators should be minimal when used in thin delicate skin or neonates

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: Not studied

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Antiseptic that denatures proteins, acts on surface of bacteria causing substantial changes in cell wall and membrane

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.